source
- GSK to begin Phase 3 trial of mRNA seasonal flu vaccine after strong Phase 2 resultsGSK announced it will start a Phase 3 study of its mRNA vaccine targeting seasonal influenza. The move follows Phase 2 data that showed the candidate produced higher immune responses than traditio…
- Novartis reports positive multiple sclerosis results with its BTK inhibitorNovartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area. The result highlights the…